The aberrant expression of BCL2 and of other members of the BCL2 family is well-described in follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and in acute myeloid leukemia (AML)3,4. This evidence concerns the gene BCL2 and mantle cell lymphoma.